Ketanserin in combination with beta‐adrenergic receptor blocking agents in the treatment of essential hypertension.

Hedner, Thomas; Persson, Bengt

doi:10.1111/j.1365-2125.1984.tb02540.x

Cited by 18 publications

(5 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…4). The magnitude of the blood pressure reduction by ketanserin in combination with these agents again was proportional to the initial blood pressure [Hedner and Persson, 1984;Wing et al, 1984;and unpublished data].…”

Section: Comparison and Combination With Other Antihypertensive Agentsmentioning

confidence: 96%

Ketanserin: A novel cardiovascular drug

Symoens

Janssens

1986

Drug Development Research

View full text Add to dashboard Cite

Symoens, J. and M. Janssens: Ketanserin: A novel cardiovascular drug. Drug Dev. Res. 8:159-172, 1986. Extensive clinical investigation has shown that ketanserin is an effective first-line antihypertensive agent with particular advantages in older patients. It has a favorable hemodynamic profile and seems devoid of serious side-effects. Clinical studies in various diseases indicate a gradual improvement of the microcirculation, which is compatible with selective serotonin S2-antagonism. Ketanserin has a favorable influence on several cardiovascular risk factors. Preliminary data suggest that it has vascular protective effects in patients with atherosclerosis.

show abstract

Section: Comparison and Combination With Other Antihypertensive Agentsmentioning

confidence: 96%

Ketanserin: A novel cardiovascular drug

Symoens

Janssens

1986

Drug Development Research

View full text Add to dashboard Cite

show abstract

“…The response to ketanserin was similar whether it was used as monotherapy or in addition to bendrofluazide or atenolol. The antihypertensive effect of ketanserin has varied widely in published placebo-controlled studies, ranging from 19/12 mm Hg (Hedner et al, 1984) to 5/4 mm Hg (Waal-Manning et al, 1985) (Table 3). Such variability is to be expected when comparing studies which have included only small numbers of patients.…”

Section: Discussionmentioning

confidence: 99%

“…., 1985;Hedner et al, 1985) but not others (Staessen et al, 1985). (Hedner et al, 1984) to 5/4 mm Hg (Waal-Manning et al, 1985) (Table 3). Such variability is to be expected when comparing studies which have included only small numbers of patients.…”

Section: Other Measurementsmentioning

confidence: 94%

See 1 more Smart Citation

Ketanserin in essential hypertension: use as monotherapy and in combination with a diuretic or beta‐adrenoceptor antagonist.

Cameron

Waller

Ramsay

1987

Brit J Clinical Pharma

View full text Add to dashboard Cite

1 The antihypertensive efficacy and tolerability of twice-daily treatment with the 5-hydroxytryptamine antagonist ketanserin were examined in a double-blind, placebocontrolled trial of 7 weeks duration in 56 hypertensive patients. Twenty were untreated, 20 were already taking bendrofluazide 5 mg daily, and 16 were already taking atenolol 100 mg daily. Randomisation was stratified to compare ketanserin with placebo as monotherapy (n = 20), when added to bendrofluazide (n = 20), and when added to atenolol (n = 16). 2 The antihypertensive effect of ketanserin in all patients completing the study (mean daily dose 71 mg) was 10/6 mm Hg supine (P < 0.01/P < 0.01) and 6/6 mm Hg standing (NS/P < 0.01) when blood pressure was measured 2 h after the morning dose. Responses were similar in patients taking ketanserin as monotherapy, in addition to bendrofluazide, and in addition to atenolol, with reductions in mean arterial pressure of 4.6, 7.4 and 8.9 mm Hg respectively. 3 Ketanserin had no antihypertensive effect when measured 14 h after the last dose. The rise in blood pressure between 2 and 14 h after dosing was 11/4 mm Hg supine (P < 0.01/ NS) and 8/5 mm Hg standing (P < 0.05/P < 0.05). 4 The antihypertensive response to ketanserin was positively related to initial blood pressure and, independent of this, to age. It was not related to plasma concentrations of ketanserin or ketanserinol. 5 Five of 28 patients taking ketanserin discontinued treatment because of side-effects, compared with one of 28 patients taking placebo. Ketanserin treatment increased body weight by 1.0 kg (P < 0.05) and prolonged the corrected QT interval by 14 ms (P < 0.01). 6 Ketanserin has only modest antihypertensive efficacy when used as monotherapy, when added to a thiazide, or when added to a 13-adrenoceptor blocker. A twice-daily dosing regimen does not seem satisfactory.

show abstract

“…Ketanserin, a selective antagonist of 5hydroxytryptamine (5-HT) at 5-HT2 receptors with some additional otl-adrenoceptor antagonist Correspondence: Dr L. E. Ramsay, University Department of Therapeutics, Royal Hallamshire Hospital, Sheffield S10 2JF *Present address: Glasgow Blood Pressure Clinic, Western Infirmary, Glasgow Gll 6NT activity, lowers blood pressure in hypertensive patients (Wenting et al, 1982;Hedner & Persson, 1984;McGourty et al, 1985). In an observerblind, parallel-group study lasting 6 months we have compared the effects of ketanserin and slow-release nifedipine when added to treatment of hypertensive patients uncontrolled by a thiazide plus P-adrenoceptor blocker.…”

Section: Introductionmentioning

confidence: 99%

Comparison of ketanserin and slow‐release nifedipine added to the treatment of hypertensive patients uncontrolled by a thiazide diuretic plus beta‐adrenoceptor blocker.

Waller¹,

Solomon²,

Ramsay³

1987

Brit J Clinical Pharma

View full text Add to dashboard Cite

1 Ketanserin or slow-release nifedipine were added to the treatment of 24 patients with hypertension uncontrolled by a thiazide diuretic plus 13-adrenoceptor antagonist in an observer-blind, randomised parallel-group study of 6 months duration. 2 At 6 months the mean falls in supine blood pressure were for ketanserin (mean daily dose 77 mg) 7/5 mm Hg and for nifedipine (mean daily dose 62 mg) 27/10 mm Hg. The difference between the treatments was significant for systolic blood pressure (P < 0.02) and mean arterial pressure (P < 0.05). Six nifedipine-treated patients reached target blood pressure, compared with one patient with ketanserin (P < 0.02). 3 One patient taking nifedipine, and nonetaking ketanserin withdrew because of sideeffects. The tolerability of the two drugs was broadly similar. 4 Ketanserin treatment was associated with significant changes in supine pulse rate (-8 beats min-', P < 0.05) and corrected QT interval (+27 ms, P < 0.05). Nifedipine treatment had no effect on these variables. The change in pulse rate was significantly different between the groups. 5 In patients treated with a diuretic and ,3-adrenoceptor blocker who required additional treatment ketanserin was significantly inferior to nifedipine.

show abstract

Ketanserin in combination with beta‐adrenergic receptor blocking agents in the treatment of essential hypertension.

Cited by 18 publications

References 17 publications

Ketanserin: A novel cardiovascular drug

Ketanserin: A novel cardiovascular drug

Ketanserin in essential hypertension: use as monotherapy and in combination with a diuretic or beta‐adrenoceptor antagonist.

Comparison of ketanserin and slow‐release nifedipine added to the treatment of hypertensive patients uncontrolled by a thiazide diuretic plus beta‐adrenoceptor blocker.

Contact Info

Product

Resources

About